{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:55:43Z","timestamp":1792076143031,"version":"4.4.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The coprimary efficacy outcomes were (1) proportion of participants with Investigator\u2019s Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, \u22129.2; 95% CI, \u221211.5 to \u22126.9;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; MVOR-2: TD, \u22126.8; 95% CI, \u22128.9 to \u22124.8;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and doxycycline (MVOR-1: TD, \u22124.7; 95% CI, \u22126.7 to \u22122.8;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; MVOR-2: TD, \u22123.5; 95% CI, \u22125.4 to \u22121.6;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifiers:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05296629\">NCT05296629<\/jats:ext-link>\n                      and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05343455\">NCT05343455<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.6542","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:02:49Z","timestamp":1741172569000},"page":"499","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea"],"prefix":"10.1001","volume":"161","author":[{"given":"Neal","family":"Bhatia","sequence":"first","affiliation":[{"name":"Therapeutics Clinical Research, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"JDR Dermatology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[{"name":"Sanova Dermatology, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[{"name":"Dermatology Consulting Services, High Point, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Sidgiddi","sequence":"additional","affiliation":[{"name":"Journey Medical Corporation, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MVOR-1 and MVOR-2 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Dawes","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Dhawan","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn Elizabeth","family":"George","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Hull","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Haber","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Adelglass","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Amster","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Francisco L.","family":"Badar","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureka","family":"Bollepalli","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Davis","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"De Valle","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fivenson","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Fried","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M.","family":"Jones","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Kempers","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A.","family":"Kerdel","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Gold","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkas E.","family":"Lebovits","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Bhatia","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Lee","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"McCune","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Grekin","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Nahm","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Santander","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Schleicher","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier F.","family":"Chang","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Miller","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo M.","family":"Allende","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Armas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan Poynot","family":"Couvillion","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess J.","family":"DeMaria","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Flores","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa Greene","family":"Knoepp","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Lain","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan B.","family":"Vissing","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Logan","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy E.","family":"Owen","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody Lynn","family":"Stone","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet C.","family":"DuBois","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Vargas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Wiltz","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Steven","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Guenthner","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Burgess","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Niesmann","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Rossbacher","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Zimmer","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarna","family":"Ekanayake-Bohlig","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Dominicus","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weirich","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Schwarz","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja C.","family":"Fischer","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Br\u00fcning","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Gerlach","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Amann","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi240074r1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis.","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240074r2","first-page":"187","article-title":"Rosacea: diagnosis and treatment.","volume":"92","author":"Oge\u2019","year":"2015","journal-title":"Am Fam Physician"},{"issue":"5","key":"doi240074r3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/bjd.18420","article-title":"Recommendations for rosacea diagnosis, classification and management: update from the Global Rosacea Consensus 2019 Panel.","volume":"182","author":"Schaller","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi240074r4","article-title":"Interventions for rosacea.","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"doi240074r5","first-page":"17","article-title":"Update on the management of rosacea from the American Acne & Rosacea Society (AARS).","volume":"12","author":"Del Rosso","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"doi240074r6","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents.","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis"},{"issue":"3","key":"doi240074r7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2340\/0001555572178179","article-title":"Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline.","volume":"72","author":"Akamatsu","year":"1992","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"doi240074r8","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1902\/jop.2008.080051","article-title":"Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models.","volume":"79","author":"Cazalis","year":"2008","journal-title":"J Periodontol"},{"issue":"2","key":"doi240074r9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.","volume":"63","author":"Griffin","year":"2011","journal-title":"Pharmacol Res"},{"issue":"1","key":"doi240074r10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4049\/jimmunol.176.1.567","article-title":"Doxycycline modulates nitric oxide production in murine lung epithelial cells.","volume":"176","author":"Hoyt","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"doi240074r11","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1128\/AAC.01540-08","article-title":"Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.","volume":"53","author":"Ishikawa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"doi240074r12","first-page":"1807","article-title":"Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.","volume":"25","author":"Pruzanski","year":"1998","journal-title":"J Rheumatol"},{"issue":"3","key":"doi240074r13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/0929867013373598","article-title":"Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.","volume":"8","author":"Ryan","year":"2001","journal-title":"Curr Med Chem"},{"issue":"2","key":"doi240074r14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0266-4356(94)90137-6","article-title":"Effects of antibiotics on human polymorphonuclear leukocyte chemotaxis in vitro.","volume":"32","author":"Ueyama","year":"1994","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"3","key":"doi240074r16","first-page":"153","article-title":"Clinical significance of brand versus generic formulations: focus on oral minocycline.","volume":"77","author":"Del Rosso","year":"2006","journal-title":"Cutis"},{"issue":"8","key":"doi240074r17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002086.pub2","article-title":"Minocycline for acne vulgaris: efficacy and safety.","volume":"2012","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"doi240074r18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/antibiotics10070757","article-title":"A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea.","volume":"10","author":"Martins","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"12","key":"doi240074r20","first-page":"16","article-title":"Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial.","volume":"14","author":"Tsianakas","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"issue":"20","key":"doi240074r21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"doi240074r22","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jaad.2014.05.044","article-title":"Reliability of Clinician Erythema Assessment grading scale.","volume":"71","author":"Tan","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi240074r23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi240074r24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi240074r25","article-title":"Minocycline-induced hyperpigmentation.","volume":"4","author":"Fiscus","year":"2014","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"1","key":"doi240074r26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000017852","article-title":"Comedonal diffusion of minocycline in acne.","volume":"196","author":"Chosidow","year":"1998","journal-title":"Dermatology"},{"issue":"8","key":"doi240074r27","first-page":"14","article-title":"Nonantibiotic properties of tetracyclines in rosacea and their clinical implications.","volume":"14","author":"Del Rosso","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"doi240074r28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic.","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"2","key":"doi240074r29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00011-016-0999-x","article-title":"Minocycline affects human neutrophil respiratory burst and transendothelial migration.","volume":"66","author":"Parenti","year":"2017","journal-title":"Inflamm Res"},{"key":"doi240074r30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","article-title":"Determination of minimum inhibitory concentrations.","volume":"48","author":"Andrews","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"doi240074r31","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.","volume":"6","author":"Fowler","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi240074r32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1365-2133.2001.03956.x","article-title":"Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.","volume":"144","author":"Ross","year":"2001","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi240074r33","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1086\/598510","article-title":"Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.","volume":"48","author":"Schwartz","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"9","key":"doi240074r34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s12325-016-0380-z","article-title":"Topical ivermectin 10 mg\/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments.","volume":"33","author":"Steinhoff","year":"2016","journal-title":"Adv Ther"},{"issue":"625","key":"doi240074r36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8077","article-title":"Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.","volume":"13","author":"Jo","year":"2021","journal-title":"Sci Transl Med"},{"issue":"9","key":"doi240074r37","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1902\/jop.2000.71.9.1472","article-title":"Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility.","volume":"71","author":"Thomas","year":"2000","journal-title":"J Periodontol"},{"key":"doi240074r35"},{"key":"doi240074r15","unstructured":"Oracea. Prescribing information. Galderma Laboratories; 2022. Accessed February 6, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050805s002lbl.pdf"},{"key":"doi240074r19","unstructured":"Minocin. Prescribing information. Triax Pharmaceuticals; 2010. Accessed February 5, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050649023lbl.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2830693\/jamadermatology_bhatia_2025_oi_240074_1747728352.5315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:00:31Z","timestamp":1747825231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2830693"}},"subtitle":["Two Phase 3 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.6542","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}